首页 | 本学科首页   官方微博 | 高级检索  
检索        

益丹内异方治疗子宫内膜异位症的临床疗效观察
引用本文:房素萍,王茵,沈观印,方广虹,曹霖,蔡毅.益丹内异方治疗子宫内膜异位症的临床疗效观察[J].生殖与避孕,2007,27(8):537-540.
作者姓名:房素萍  王茵  沈观印  方广虹  曹霖  蔡毅
作者单位:1. 上海市计划生育科学研究所附属博康生殖医学医院,上海,200032
2. 国家人口和计划生育委员会计划生育药具重点实验室,上海市计划生育科学研究所,上海,200032
3. 武警上海市总队医院,上海,201103
摘    要:目的:观察益丹内异方治疗子宫内膜异位症(EMs)的疗效。方法:由腹腔镜检查诊断为EMs不孕症患者127例,在腹腔镜下作相应的治疗后,按随机号对其中66例进行中药益丹内异方治疗(实验组):口服益丹内异中药水煎剂,每日1剂,分早晚2次顿服;另61例为对照组,采用传统的达那唑阴道栓治疗,50mg/次,bid;所有患者经6个月治疗后,进行临床疗效比较。结果:治疗后实验组不孕症者受孕率为53.0%,总有效率为87.9%;对照组不孕症者受孕率为30.0%,总有效率为52.5%,二组间有显著差异(P<0.05)。在免疫调节方面,实验组抗子宫内膜抗体(EMAb)转阴率为100.0%,对照组为53.8%,二者有极显著差异(P<0.01);实验组和对照组在用药期间血清癌抗原(CA125)值均降低,自身对照服药前后二组均有极显著差异(P<0.01)。结论:中药益丹内异方治疗EMs疗效可靠,无毒副作用且用药期间不影响自然排卵及受孕。

关 键 词:子宫内膜异位症(EMs)  腹腔镜检查  CA125  抗子宫内膜抗体(EMAb)
文章编号:0253-357X(2007)08-0537-04
修稿时间:2007-06-26

Clinical Effect of the Traditional Chinese Medicine (Yidanneiyifang)on Treating Endometriosis
Su-ping FANG,Yin WANG,Guan-yin SHENG,Guang-hong FANG,Lin CAO,Yi CAI.Clinical Effect of the Traditional Chinese Medicine (Yidanneiyifang)on Treating Endometriosis[J].Reproduction and Contraception,2007,27(8):537-540.
Authors:Su-ping FANG  Yin WANG  Guan-yin SHENG  Guang-hong FANG  Lin CAO  Yi CAI
Institution:1. Bokang Reproductive Hospital, Shanghai Institute of Planned Parenthood Research, Shanghai, 200032;2. National Laboratory of Contraceptives and Divices Research, Shanghai Institute of Planned Parenthood Research, Shanghai, 200032;3. Armed Police Hospital of Shanghai, Shanghai, 201103
Abstract:Objective: To observe the effect of the Traditional Chinese Medicine——Yidanneiyifang on treating endometriosis. Methods: A total of 127 infertile women with endometriosis (EMs) diagnosed by laparoscopy were collecte, and divided into two groups, 66 infertile women (experimental group) received water decoction of Yidanneiyifang orally, one dosage was taken for twice a day; 61 infertile women (control group) were treated with traditional Danazol decoction, 50 mg, bid. The curative effect was observed after 6 months. Results: After treated, the pregnancy rate and the total effective rate were 53.0% and 87.9% respectively in experimental group, there was a significant diference compared with those in control group (30.0% and 52.5%, P<0.05). In immunoregulation, the transnegative rate of antiendometrial antibody (EMAb) was 100%, it was significantly different from the control (53.8%, P<0.01). The value of CA125 was decreased in both groups during administration, there was a significant difference between before and after administration of self-control drug in the two groups, respectively. Conclusion: The effect of Yidanneiyifang on treating EMs is credibility, it has no toxicity and side effect and will not influence natural ovulation and impregnation during administration.
Keywords:CA125
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号